Interestingly, the prognostic power of mdig was also noted for poorer relapse-free survival of the breast cancer patients (Fig. 5C) and poorer progress-free survival of the ovarian cancer patients (Fig. 5D). Here, RIOX2 is linked to ovarian carcinoma.